Agios Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Agios Pharmaceuticals

13/02/2025 14:31

* Agios Pharmaceuticals Inc  AGIO.OQ  reported a quarterly
adjusted loss of $1.44​​ per share for the quarter ended
December 31, higher than the same quarter last year, when the
company reported EPS of $-1.72.  The mean expectation of
nine analysts for the quarter was for a loss of $1.69 per share.
Wall Street expected results to range from $-1.84 to $-1.54 per
share.
    * Revenue rose 51.1% to $10.73 million from a year ago;
analysts
expected $9.33 million. 
    * Agios Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of $1.44​.
    * The company reported a quarterly loss of $96.52 million.
    * Agios Pharmaceuticals Inc shares had fallen by 0.2% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 0.2%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Agios
Pharmaceuticals Inc is $56.50 
This summary was machine generated from LSEG data February 13 at
02:31 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2024      -1.69          -1.44          Beat
 Sep. 30 2024      1.11           -2.42          Missed
 Jun. 30 2024      -1.60          -1.69          Missed
 Mar. 31 2024      -1.65          -1.45          Beat